- Order intake up 72.3 percent; sales revenue up 53.9 percent; underlying EBITDA margin 34.3 percent
- Both divisions with strong double-digit growth; significant demand momentum generated by the production of coronavirus vaccines and test kits as well as excellent development of acquisitions
- Forecast raised at the beginning of July for 2021 confirmed
PR Newswire
GĂ–TTINGEN, Germany, Oct. 20, 2021